Silence Therapeutics rewarded for RNAi molecules
This article was originally published in Scrip
Executive Summary
Silence Therapeutics says that its partner Quark Pharmaceuticalswill evaluate one of its siRNA (small interfering RNA) molecules in a Phase II clinical trial withPfizer. The trial has triggered a $1.9 million milestone for the UK company.